Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 11, 2016, Pages 3157-3167

  Rees, Vanessa E ^a   Bulitta, Jürgen B ^b   Oliver, Antonio ^c   Tsuji, Brian T ^d   Rayner, Craig R ^a,e   Nation, Roger L ^a   Landersdorfer, Cornelia B ^a,d  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF FLORIDA   (United States)

^c HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^d UNIVERSITY AT BUFFALO   (United States)

^e D3 Medicine LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOBRAMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; TIME FACTOR;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; PSEUDOMONAS AERUGINOSA; TIME FACTORS; TOBRAMYCIN;

EID: 84994499801     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw297     Document Type: Article

References (63)

1. Hede K. Antibiotic resistance: an infectious arms race. Nature 2014; 509: S2-3.
2. Chastre J. Evolving problems with resistant pathogens. Clin Microbiol Infect 2008; 14 Suppl 3: 3-14.
3. Cully M. Public health: the politics of antibiotics. Nature 2014; 509: S16-7.
4. Spellberg B, Blaser M, Guidos RJ et al. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 2011; 52 Suppl 5: S397-428.
5. Macia MD, Blanquer D, Togores B et al. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Chemother 2005; 49: 3382-6.
6. Plasencia V, Borrell N, Macia MD et al. Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. Antimicrob Agents Chemother 2007; 51: 2574-81.
7. Milatovic D, Braveny I. Development of resistance during antibiotic therapy. Eur J Clin Microbiol 1987; 6: 234-44.
8. Lambert PA. Mechanisms of antibiotic resistance in Pseudomonas aeruginosa. J R Soc Med 2002; 95: 22-6.
9. Bulitta JB, Ly NS, Landersdorfer CB et al. Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling. Antimicrob Agents Chemother 2015; 59: 2315-27.
10. Loh B, Grant C, Hancock RE. Use of the fluorescent probe 1-N-phenylnaphthylamine to study the interactions of aminoglycoside antibiotics with the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1984; 26: 546-51.
11. Morita Y, Tomida J, Kawamura Y. MexXY multidrug efflux system of Pseudomonas aeruginosa. Front Microbiol 2012; 3: 408.
12. Poole K. Pseudomonas aeruginosa: resistance to the max. Front Microbiol 2011; 2: 65.
13. Guenard S, Muller C, Monlezun L et al. Multiple mutations lead to MexXY-OprM-dependent aminoglycoside resistance in clinical strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2014; 58: 221-8.
14. Poole K. Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49: 479-87.
15. Oliver A. Mutators in cystic fibrosis chronic lung infection: prevalence, mechanisms, and consequences for antimicrobial therapy. Int J Med Microbiol 2010; 300: 563-72.
16. Oliver A, Mena A. Bacterial hypermutation in cystic fibrosis, not only for antibiotic resistance. Clin Microbiol Infect 2010; 16: 798-808.
17. Oliver A, Canton R, Campo P et al. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000; 288: 1251-4.
18. Miller JH. Spontaneous mutators in bacteria: insights into pathways of mutagenesis and repair. Annu Rev Microbiol 1996; 50: 625-43.
19. Oliver A, Baquero F, Blazquez J. The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants. Mol Microbiol 2002; 43: 1641-50.
20. Feliziani S, Lujan AM, Moyano AJ et al. Mucoidy, quorum sensing, mismatch repair and antibiotic resistance in Pseudomonas aeruginosa from cystic fibrosis chronic airways infections. PLoS One 2010; 5: e12669.
21. Ferroni A, Guillemot D, Moumile K et al. Effect of mutator P. aeruginosa on antibiotic resistance acquisition and respiratory function in cystic fibrosis. Pediatr Pulmonol 2009; 44: 820-5.
22. LeClerc JE, Li B, Payne WL et al. High mutation frequencies among Escherichia coli and Salmonella pathogens. Science 1996; 274: 1208-11.
23. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10; quiz 1-2.
24. Ioannides-Demos LL, Liolios L, Wood P et al. Changes in MIC alter responses of Pseudomonas aeruginosa to tobramycin exposure. Antimicrob Agents Chemother 1998; 42: 1365-9.
25. Ambrose PG, Bhavnani SM, Rubino CM et al. Pharmacokineticspharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44: 79-86.
26. Smyth AR, Bhatt J. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev 2014; issue 2: CD002009.
27. Smyth A, Tan KH, Hyman-Taylor P et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis-the TOPIC study: a randomised controlled trial. Lancet 2005; 365: 573-8.
28. Burkhardt O, Lehmann C, Madabushi R et al. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? J Antimicrob Chemother 2006; 58: 822-9.
29. Rees VE, Bulitta JB, Nation RL et al. Shape does matter: short highconcentration exposure minimizes resistance emergence for fluoroquinolones in Pseudomonas aeruginosa. J Antimicrob Chemother 2015; 70: 818-26.
30. Mena A, Smith EE, Burns JL et al. Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation. J Bacteriol 2008; 190: 7910-7.
31. EUCAST. Antimicrobial Wild Type Distributions of Microorganisms. http://www.eucast.org/mic_distributions_and_ecoffs/.
32. Conil JM, Georges B, Ruiz S et al. Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations. Br J Clin Pharmacol 2011; 71: 61-71.
33. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Ninth Edition: Approved Standard M07-A9. CLSI, Wayne, PA, USA, 2012.
34. Oliver A, Levin BR, Juan C et al. Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections. Antimicrob Agents Chemother 2004; 48: 4226-33.
35. Maidhof H, Johannsen L, Labischinski H et al. Onset of penicillininduced bacteriolysis in staphylococci is cell cycle dependent. J Bacteriol 1989; 171: 2252-7.
36. Landersdorfer CB, Ly NS, Xu H et al. Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing design. Antimicrob Agents Chemother 2013; 57: 2343-51.
37. Bulitta JB, Ly NS, Yang JC et al. Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53: 46-56.
38. Tsuji BT, Bulitta JB, Brown T et al. Pharmacodynamics of early, highdose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations. J Antimicrob Chemother 2012; 67: 2182-90.
39. Lin HY, Landersdorfer CB, London D et al. Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system. PLoS Comput Biol 2011; 7: e1001073.
40. Zhu ZY, Li RC. Impact of pharmacokinetics on the postantibiotic effect exhibited by Pseudomonas aeruginosa following tobramycin exposure: application of an in-vitro model. J Antimicrob Chemother 1998; 42: 61-5.
41. Hocquet D, Vogne C, El Garch F et al. MexXY-OprM efflux pump is necessary for adaptive resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother 2003; 47: 1371-5.
42. Daikos GL, Jackson GG, Lolans VT et al. Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J Infect Dis 1990; 162: 414-20.
43. Ly NS, Bulitta JB, Rao GG et al. Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance. J Antimicrob Chemother 2015; 70: 1434-42.
44. Bulitta JB, Yang JC, Yohonn L et al. Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model. Antimicrob Agents Chemother 2010; 54: 2051-62.
45. Bulitta JB, Bingolbali A, Shin BS et al. Development of a new pre-and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT. AAPS J 2011; 13: 201-11.
46. Matthews I, Kirkpatrick C, Holford N. Quantitative justification for target concentration intervention-parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. Br J Clin Pharmacol 2004; 58: 8-19.
47. Hennig S, Norris R, Kirkpatrick CM. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis-a population pharmacokinetic study. Br J Clin Pharmacol 2008; 65: 502-10.
48. Hennig S, Standing JF, Staatz CE et al. Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis. Clin Pharmacokinet 2013; 52: 289-301.
49. Pagkalis S, Mantadakis E, Mavros MN et al. Pharmacological considerations for the proper clinical use ofaminoglycosides. Drugs 2011; 71: 2277-94.
50. Vogne C, Aires JR, Bailly C et al. Role of the multidrug efflux system MexXY in the emergence of moderate resistance to aminoglycosides among Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2004; 48: 1676-80.
51. Jeannot K, Sobel ML, El Garch F et al. Induction of the MexXY efflux pump in Pseudomonas aeruginosa is dependent on drug-ribosome interaction. J Bacteriol 2005; 187: 5341-6.
52. Hay T, Fraud S, Lau CH et al. Antibiotic inducibility of the mexXY multidrug efflux operon of Pseudomonas aeruginosa: involvement of the MexZ anti-repressor ArmZ. PLoS One 2013; 8: e56858.
53. Hancock RE, Raffle VJ, Nicas TI. Involvement of the outer membrane in gentamicin and streptomycin uptake and killing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1981; 19: 777-85.
54. Kadurugamuwa JL, Clarke AJ, Beveridge TJ. Surface action of gentamicin on Pseudomonas aeruginosa. J Bacteriol 1993; 175: 5798-805.
55. Li RC, Lee SW, Kong CH. Correlation between bactericidal activity and postantibiotic effect for five antibiotics with different mechanisms of action. J Antimicrob Chemother 1997; 40: 39-45.
56. Craig WA. Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man. J Antimicrob Chemother 1993; 31 Suppl D: 149-58.
57. Isaksson B, Nilsson L, Maller R et al. Postantibiotic effect of aminoglycosides on gram-negative bacteria evaluated by a new method. J Antimicrob Chemother 1988; 22: 23-33.
58. Karlowsky JA, Zhanel GG, Davidson RJ et al. Postantibiotic effect in Pseudomonas aeruginosa following single and multiple aminoglycoside exposures in vitro. J Antimicrob Chemother 1994; 33: 937-47.
59. Bundtzen RW, Gerber AU, Cohn DL et al. Postantibiotic suppression of bacterial growth. Rev Infect Dis 1981; 3: 28-37.
60. Barclay ML, Begg EJ. Aminoglycoside adaptive resistance: importance for effective dosage regimens. Drugs 2001; 61: 713-21.
61. Barclay ML, Begg EJ, Chambers ST. Adaptive resistance following single doses of gentamicin in a dynamic in vitro model. Antimicrob Agents Chemother 1992; 36: 1951-7.
62. Barclay ML, Begg EJ, Chambers ST et al. The effect of aminoglycosideinduced adaptive resistance on the antibacterial activity of other antibiotics against Pseudomonas aeruginosa in vitro. J Antimicrob Chemother 1996; 38: 853-8.
63. Daikos GL, Lolans VT, Jackson GG. First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. Antimicrob Agents Chemother 1991; 35: 117-23.